Novartis’ NVA237 improves lung function in pulmonary disease patients
Swiss drug maker Novartis said results from a phase three study remarkably improved lung function in a similar way to a rival drug.
Proactive Investors
Inherent value to be “developed and extracted” at Amphion
Amphion Innovations (LON:AMP) said it believes there is “significant inherent value to be developed and extracted” from its partner companies, when it released its annual […]
Neostem’s Suzhou Eyre receives Chinese Regulatory Approval For 6th Production Line
NeoStem announced Monday that its subsidiary, Suzhou Eyre Pharmaceuticals, has received approval for its sixth production line.
ImmunoCellular Therapeutics Expands Phase 2 Trial For Brain Cancer Treatment
ImmunoCellular Therapeutics has expanded the number of sites for its phase two clinical trial ofa potential vaccine treatment for brain cancer.
OXiGENE Releases Promising Phase Two Data For Lung Cancer Drug
OXiGENE shares rose in pre-market trading Monday
Emergent BioSolutions Acquires Rights To Lymphoma Drug
Emergent BioSolutions has acquired the rights to Zanolimumab, an investigational and late-stage antibody cancer therapy.
YM BioSciences Receives Orphan Drug Designation In EU For Myelofibrosis Treatment
YM BioSciences has received orphan drug designation from the European Commission for CYT387, a treatment for myelofibrosis, a type of chronic leukemia.
ReNeuron Treats Third Stroke Patient In Phase I Trials Of Stem Cell Therapy
ReNeuron said this morning the last of the stroke patients in the initial dosing group has been treated with the group’s new stem cell therapy.
NeoStem To Drive Shareholder Value, Says Rodman & Renshaw
NeoStem said Thursday that equity research firm Rodman & Renshaw re-iterated the multi-faceted stem cell company’s market outperform rating, based on “multiple milestones to drive shareholder value”.
Renovo Actively Progressing With Plans To Maximize Returns After Juvista Failure
Renovo Group (LON:RNVO) confirmed today it will be left with £33 million if it presses ahead with plans to reduce its headcount by 100.